Update: Impact BioMedical Inc. (NYSE: IBO) Hits Green Stride Early, Returns to the #1 Spot on Our Watchlist

Sponsored* See Why Impact BioMedical Inc. (NYSE: IBO) Returns to the Top of Our Watchlist for This Morning! Impact BioMedical Inc. (NYSE: IBO is Our #1 Potential Breakout  Idea for Morning… Consider adding Impact BioMedical Inc. (NYSE: IBO) to the top of your watchlist early this morning! Here’s why Impact BioMedical Inc. (NYSE: IBO) is Getting Our  Attention Again… Impact BioMedical Inc. (NYSE: IBO) comes backed by several potential catalysts including:  Low Float: With under 5.4M shares in its public float, Impact BioMedical Inc. (NYSE: IBO) could see significant volatility! Recent Market Recognition: Impact BioMedical Inc. (NYSE: IBO) witnessed an approximate 120% move last month. Strong Intellectual Property Portfolio: With 39 issued patents and 50 pending applications worldwide! Insider Ownership: currently exceeding 55%, this is one  company to keep on your radar! November 18, 2024 Dear Reader, Hey, do you have Impact BioMedical Inc. (NYSE: IBO) on your screen yet?  Impact BioMedical Inc. (NYSE: IBO) went green early and now could be a good time to pull it up. Here’s why… There are few sectors in the market where small companies can evolve into big players almost overnight, and the field of disease treatment is one of them.   In the race to develop life-changing therapies, companies making significant progress can often spark widespread interest. Impact BioMedical Inc. (NYSE: IBO) brings a unique approach, merging cutting-edge science with natural solutions in ways few others can. By addressing key health challenges with sustainable and innovative solutions, Impact BioMedical Inc. (NYSE: IBO) is developing a diverse product line that spans antiviral treatments, natural insect repellents, sugar substitutes, and biopharmaceuticals.  Impact BioMedical Inc. (NYSE: IBO) is a company committed to advancing healthcare and wellness through groundbreaking scientific research and proprietary technologies.  With 39 issued patents and 50 pending applications worldwide, and an approximate 120% move last month, this company is pushing boundaries in wellness. And with insider ownership currently exceeding 55%, this is one company to keep on your radar. Here’s a closer look at the company’s technologies, intellectual property, partnerships, and market impact. Core Technologies and Intellectual Property Impact BioMedical Inc. (NYSE: IBO)’s core strength lies in its proprietary technologies and strong intellectual property (IP) portfolio.  With 39 issued patents and 50 pending applications worldwide, the company protects its technological advancements, ensuring they retain a competitive edge in the biotech and wellness markets.  The intellectual property covers multiple areas of healthcare and wellness, positioning Impact BioMedical Inc. (NYSE: IBO) to bring unique, transformative products to market. Key Product Innovations 3F™ Functional Fragrances: Applications: Antiviral and insect repellent Description: The 3F™ line includes fragrances formulated from specialized botanical ingredients, such as terpenes, which offer natural insect-repellent and antimicrobial properties. These fragrances aim to provide an eco-friendly and effective solution for personal and household use, catering to consumers who prefer natural wellness products. Market Potential: According to WHO, vector-borne diseases represent over 17% of all infectious diseases globally. By addressing this need, 3F™ Functional Fragrances provides a timely and innovative approach to reducing disease transmission through natural insect repellents, developed in collaboration with Chemia Corp.  Equivir/G: Applications: Over-the-counter (OTC) antiviral treatment  and health supplement Description: Built with a unique blend of FDA GRAS (Generally Recognized as Safe) polyphenols, Equivir targets respiratory health by offering a potential daily supplement to strengthen immunity against viral threats. The product’s formulation has demonstrated broad antiviral properties and is aimed at addressing the growing demand for immune-supportive supplements. Market Potential: In 2019 alone, there were approximately 17.2B cases of upper respiratory tract infections worldwide. Equivir addresses this vast need by providing an accessible solution to enhance respiratory health and viral immunity. Laetose: Applications: Sugar substitute and dietary supplement Description: Laetose is a sugar substitute that combines multiple sugars with inositol, reducing the inflammatory and metabolic effects associated with sugar intake. This product aligns with the shift toward healthier dietary options, especially given rising health concerns about sugar-related issues like obesity and diabetes. Market Potential: With the U.S. refined sugar market valued at approximately $12B, Laetose presents a healthier alternative to traditional sugars. By lowering glycemic response, Laetose meets the growing consumer demand for metabolic-friendly food options. Linebacker: A Promising Platform for Cancer, Inflammatory, and Neurological Treatments Applications: Linebacker is designed to address critical treatment areas, including cancer, inflammatory diseases, and neurological disorders. Description: Linebacker is a polyphenol-based platform engineered to boost the efficacy and bioavailability of active ingredients, making it effective in both monotherapy and combination therapy.  It shows particular promise in oncology, with applications in lung and colon cancer—two of the most lethal cancer types globally.  This technology's potential also extends to addressing complex inflammatory and neurological conditions, offering a versatile approach to major health challenges. Market Potential: With lung and colon cancers among the top causes of cancer mortality worldwide, Linebacker targets an area of high unmet need.  The platform is advancing through strategic partnerships, including with ProPhase Labs, to pursue clinical applications for key disease indications.  The global lung cancer therapeutics market is expected to reach approximately $32B in 2024, climbing to around $71B by 2034.  Similarly, the global colorectal cancer therapeutics market is projected to grow from $12B in 2024 to $19B by 2034. Through Linebacker, Impact BioMedical Inc. (NYSE: IBO) is positioning itself to make significant contributions to these high-impact therapeutic areas. Expanding Biotech and Med-Tech Solutions Beyond consumer-oriented products, Impact BioMedical Inc. (NYSE: IBO) also explores innovations in biotech and med-tech, focusing on sustainability and environmental safety.  This includes: Bioplastics and Natural Preservatives: Sustainable alternatives to conventional materials, addressing environmental impacts by promoting eco-friendly solutions in consumer products. Biopharmaceuticals: The development of advanced treatments for cancer, inflammatory diseases, and neurological conditions, supporting unmet medical needs in regulated biotech markets. Strategic Partnerships for Product Development Impact BioMedical Inc. (NYSE: IBO) has forged strategic partnerships to accelerate its product development and commercialization. These collaborations include: ProPhase Labs: As a partner in developing products for oncology, neurology, and inflammatory diseases, ProPhase Labs contributes to the company’s R&D capabilities, helping to bring innovations like Linebacker to clinical relevance. Chemia Corp: Based in St. Louis, Missouri, Chemia Corp supports the 3F™ Functional Fragrances line by providing manufacturing expertise, ensuring scalability and quality for these natural, functional wellness products.  The Global Anti-Inflammatory Therapeutics Market Poised to Surpass $152B by 2033… Impact BioMedical Inc. (NYSE: IBO) Takes Strategic Steps The global anti-inflammatory therapeutics market is on a trajectory to exceed $152B by 2033, with the U.S. alone expected to capture a $42B share.  In 2023, North America led the charge with 37% of the global market, driven by rising demand for biologics, government support for biosimilars, and robust research funding.  As more people seek relief from conditions like rheumatoid arthritis, migraines, and autoimmune disorders, the demand for anti-inflammatory therapeutics continues to grow. Impact BioMedical Inc. (NYSE: IBO) is strategically positioning itself in this expansive market, leveraging its dual approach to serve both consumer and healthcare segments.  The company’s product portfolio spans from over-the-counter health supplements to regulated biotech treatments, allowing it to engage a wide spectrum of audiences—from everyday consumers seeking wellness products to healthcare providers treating chronic conditions.  By addressing both immediate wellness needs and long-term health challenges, Impact BioMedical Inc. (NYSE: IBO) is creating scalable solutions that align with market demand. The company’s focus on anti-inflammatory biologics highlights its commitment to providing innovative, targeted therapies with fewer side effects than conventional treatments.  Biologics, designed for precision and effectiveness, address a growing need for safer, more efficient solutions in managing inflammation and pain associated with various chronic conditions. Impact BioMedical Inc. (NYSE: IBO) is positioning itself at the forefront of a booming market, with a unique product strategy that aligns with both the immediate needs of consumers and the long-term growth of the healthcare sector.  As the anti-inflammatory therapeutics market grows, this approach may well put the company on a path to significant influence and market share. Commitment to Sustainable Health Solutions Impact BioMedical Inc. (NYSE: IBO)’s dedication to developing science-driven, eco-conscious products aligns with the global trend toward safer, more sustainable healthcare options. By prioritizing natural ingredients and sustainable processes, the company appeals to a growing segment of consumers seeking holistic, eco-friendly health solutions. Impact BioMedical Inc. (NYSE: IBO) stands out in the biotech and wellness sectors through its innovative technologies, strong IP portfolio, and commitment to sustainability.  With products that address significant health concerns, from immune health to cancer treatment, and strategic partnerships that enhance its capabilities, the company is poised to make a meaningful impact on health and wellness worldwide. 7 reasons why Impact BioMedical Inc. (NYSE: IBO) will be #1 on our watchlist early this morning… 1. Low Float: With less than 5.4M shares available in its public float, Impact BioMedical Inc. (NYSE: IBO) could present the potential for significant swings.  2. Recent Market Recognition: Take a look at Impact BioMedical Inc. (NYSE: IBO)’s recent move: between 10/11/2024 and 11/11/2024, it saw an approximate 120% move in a month. 3. Strong Intellectual Property Portfolio: Impact BioMedical Inc. (NYSE: IBO) holds 39 issued patents and 50 pending applications worldwide. This robust IP foundation covers multiple technologies in healthcare and wellness, helping the company maintain a competitive edge. 4. Innovative Product Line: The company has developed a diverse range of products, including antiviral treatments, natural insect repellents, sugar substitutes, and biopharmaceuticals. Each product addresses specific health needs, from respiratory health to metabolic wellness, appealing to a broad market. 5. Focus on Natural and Sustainable Solutions: Impact BioMedical Inc. (NYSE: IBO) prioritizes environmentally friendly products, aligning with the growing demand for natural, sustainable healthcare options. This includes bioplastics and natural preservatives, which offer eco-conscious alternatives to traditional products. 6. Expansive Market Potential: Impact BioMedical Inc. (NYSE: IBO)’s products target several high-demand sectors, including OTC wellness products and regulated biotech markets. By addressing issues like immune health, sugar consumption, and chronic diseases, the company has positioned itself to meet pressing global health needs. 7. Strategic Partnerships for Growth: Collaborations with established organizations like ProPhase Labs and Chemia Corp enhance Impact BioMedical Inc. (NYSE: IBO)’s R&D, manufacturing, and global distribution capabilities, helping to ensure product quality, scalability, and market reach. As a company that merges science-driven innovation with a commitment to natural and sustainable health solutions, Impact BioMedical Inc. (NYSE: IBO) stands out in the biotech and wellness sectors. With fewer than 5.4M shares in its public float, the company offers potential for volatility and short-term movement.  Its approximate 120% recent move, strong intellectual property portfolio of 39 issued patents and 50+ pending applications, and diverse product line highlight Impact BioMedical Inc. (NYSE: IBO)’s comprehensive strategy for addressing critical health challenges across multiple high-growth sectors. From antiviral treatments to eco-friendly bioplastics, Impact BioMedical Inc. (NYSE: IBO) prioritizes solutions that align with global wellness trends and environmental awareness. Through strategic partnerships with established companies like ProPhase Labs and Chemia Corp, Impact BioMedical Inc. (NYSE: IBO) is positioning itself to expand its reach and deliver timely solutions for global health challenges.  As it continues to grow, the company’s emphasis on natural, research-backed products and expansive market potential makes it a significant player in today’s wellness landscape.  Impact BioMedical Inc. (NYSE: IBO) is #1 on our watchlist early this morning. If you missed Impact BioMedical Inc. (NYSE: IBO) the last time we covered it, now’s your chance to catch up.  I’ll check in with you shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 11/17/2024 and ending on 11/18/2024 to publicly disseminate information about (IBO:US) via digital communications. Under this agreement, we have been paid twenty-two thousand five hundred USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid thirty-two thousand five hundred USD (“Funds”) for (IBO:US). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (IBO:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ibo/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice